title: Hepatocellular carcinoma associated with tumor thrombosis in the portal vein: the effects of different treatments.
abstract: OBJECTIVE
  To compare the effects of different treatments for hepatocellular carcinoma (HCC) with tumor thrombosis in the portal vein (TTPV) and evaluate the factors influencing the prognosis.
  
  
  METHODS
  One hundred and thirty-eight patients with HCC associated with TTPV, whose liver function was compensative and the tumor with TTPV can probably be resected together, were divided into four groups: conservative treatment group (n=14); chemotherapy group (n=19); surgical resection group (n=19); and surgical resection with postoperative chemotherapy group (n=64).
  
  
  RESULTS
  The median survivals of the four groups were 3.5, 7.1, 10.1 and 13.4 months, respectively. The 0.5-, 1-, 2-, and 3-year cumulative survival rates of the surgical resection with postoperative chemotherapy group were 53.7%, 37.6%, 30.7% and 14.0% respectively, which were significantly higher than those of the other three groups (P<0.05). Both univariate and multivariate analysis revealed that postoperative chemotherapeutic course was the most important factor affecting the surgical results.
  
  
  CONCLUSIONS
  If patients' liver function is compensative and tumors with TTPV can be removed together, exploration should be done. Surgical resection combined with postoperative chemotherapy can achieve the best results. More chemotherapeutic courses after surgical resection can be prescribed if the patients have good hepatic functional reserve.
authors: Liver Cancer Institute, Zhongshan Hospital, Fudan University Shanghai Medical School, 136 Yi Xue Yuan Road, Shanghai 200032, China. jiafan99@yahoo.com
authors: Jia
authors: J
authors: Fan
authors: Zhi-Quan
authors: ZQ
authors: Wu
authors: Jian
authors: J
authors: Zhou
authors: Shuang-Jian
authors: SJ
authors: Qiu
authors: Ying-Hong
authors: YH
authors: Shi
authors: Rong-Xin
authors: RX
authors: Chen
authors: Zhao-You
authors: ZY
authors: Tang
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D016461:Chemoembolization, Therapeutic / Q000379:methods*; D015331:Cohort Studies; D003131:Combined Modality Therapy; D005260:Female; D006498:Hepatectomy / Q000009:adverse effects / Q000379:methods; D006801:Humans; D008113:Liver Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009360:Neoplastic Cells, Circulating; D011169:Portal Vein; D011336:Probability; D011379:Prognosis; D012189:Retrospective Studies; D018570:Risk Assessment; D012680:Sensitivity and Specificity; D016019:Survival Analysis; D017131:Thrombectomy / Q000379:methods; D013927:Thrombosis / Q000175:diagnosis / Q000628:therapy*; D016896:Treatment Outcome